Navigation Links
Soligenix Reports First Quarter 2011 Financial Results and Reviews Accomplishments
Date:5/13/2011

PRINCETON, N.J., May 13, 2011 /PRNewswire/ -- Soligenix, Inc. (OTCBB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company, announced today its financial results for the first quarter of 2011.

Soligenix's revenues for the first quarter of 2011 were approximately $808,000 as compared to $336,000 for the first quarter of 2010. The increased revenues were primarily a result of increases in National Institutes of Health (NIH) grant revenues as the Company increased research efforts under its thermostable vaccine development program and under its FDA Orphan Products grant for the confirmatory Phase 3 clinical trial of orBec® in acute gastrointestinal Graft-versus-Host disease (GI GVHD).

Soligenix's net loss for the first quarter of 2011 was approximately $1,720,000, or $(0.01) per share, as compared to $2,136,000, or $(0.01) per share for the first quarter of 2010.

Research and development expenses for the first quarter of 2011 were approximately $1,256,000, compared to $1,598,000 for the first quarter of 2010. General and administrative expenses for the first quarter of 2011 were approximately $564,000, compared to approximately $538,000 for the first quarter of 2010.

"While the first quarter of 2011 was quite eventful for us, our primary focus continues to be the conduct of our confirmatory Phase 3 orBec® clinical trial," stated Christopher J. Schaber, PhD, President and Chief Executive Officer of Soligenix. "We remain committed to our goal of having orBec® become the first FDA-approved therapy to treat GI GVHD, an area of unmet medical need associated with high morbidity and mortality rates. On the biodefense and vaccine side of our business, we received Orphan Drug designation for RiVax™ and also executed a license on new technology that will potentially enable us to develop vaccines that are stable at elevated temperatures. We also achieved positive results of SGX202 in a canine model of rad
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Soligenix Reports Year-End 2010 Financial Results and Highlights Recent Accomplishments
2. Soligenix Receives FDA Orphan Drug Designation for RiVax™ for the Prevention of Ricin Intoxication
3. Soligenix Reports Second Quarter 2010 Financial Results and Reviews Accomplishments
4. Soligenix Announces Private Equity Financing of $5.16 Million With Its Partner Sigma-Tau and Other Institutional Investors
5. Soligenix Announces Grant of US Patent for the Treatment of Irritable Bowel Syndrome with Oral Beclomethasone Dipropionate
6. Soligenix Reports First Quarter 2010 Financial Results and Reviews Accomplishments
7. Soligenix Announces Completion of Patient Enrollment in Phase 2 Acute GVHD Prevention Clinical Trial
8. Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
9. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
10. Soligenix Reports Third Quarter 2009 Financial Results
11. Soligenix to Present at 8th Annual BIO Investor Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013  Cleveland BioLabs, Inc. (NASDAQ: CBLI) today announced that ... Marcum LLP Microcap Conference, May 30, in New ... Lyons , CPA, Chief Financial Officer of Cleveland BioLabs, ... 30 at 1:30 p.m. Eastern Time.  A live and archived ... Investors page of the Cleveland BioLabs website at www.cbiolabs.com ...
(Date:5/22/2013)... (PRWEB) May 22, 2013 Alton Housing Authority ... May 15, 2013 said that their presence has already ... bed bug sufferers avoid such big spending, My Cleaning Products ... inexpensively. , It was said in the report that to ... MCP related. Apart from that, its employees also attended a ...
(Date:5/22/2013)... 22, 2013  Moderna Therapeutics, the pioneering company developing ... enable the in vivo production of therapeutic ... will join Moderna in early July as its ... a proven leader in the design and implementation of ... discovery to translation, clinical operations and commercial preparedness. John ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 Custom ... to reporting eLearning solution using Tin Can API ... dashboard tool. CLD is a leading developer of ... medical device companies worldwide. , Tin Can ... that helps learners and trainers more accurately measure ...
Breaking Biology Technology:Cleveland BioLabs to Present at Second Annual Marcum LLP Microcap Conference 2Bed Bugs Cost Alton Housing Authority $35,000; New Help, How to Kill Bed Bugs With Less Expense, Introduced by My Cleaning Products 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 2Industry Leader John Reynders Joins Moderna Therapeutics as Chief Information Officer 3CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 2CLD Integrates Tin CAN API with its eLearning Solutions and Launches its Excelerometer Tracking Statement Dashboard 3
... the State speech that is anything less than optimistic, and ... or Democrat, riding high in the polls or battling mediocre ... the State speech to inspire, cajole and sprinkle a few ... to the state was no exception. , ,But how ...
... a visit to Sheboygan that the region could be a ... on Madison and Milwaukee. , ,A professor at Lakeland College ... work in local biotechnology companies, if the jobs were available. ... find jobs elsewhere, is a concern across Wisconsin. , ,At ...
... retrospectively reviewing what happened to major pharma and biotech companies, including ... investor perspective as reflected in a stock price and resultant valuation ... look at and value the impact of our industry. One such ... Companies to Work For 2006 published on January 11th. ...
Cached Biology Technology:How's the State of the State? It depends on what numbers are crunched 2How's the State of the State? It depends on what numbers are crunched 3Biotech leads list of top U.S. companies to work for 2Biotech leads list of top U.S. companies to work for 3Biotech leads list of top U.S. companies to work for 4Biotech leads list of top U.S. companies to work for 5
(Date:5/21/2013)... American Chemical Society (ACS), the world,s largest scientific ... National Meeting & Exposition, September 8-12, 2013, in ... Indiana Convention Center and at area hotels. , ... that span science,s horizons from astronomy to ... and online journalists a rich assortment of spot ...
(Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
(Date:5/21/2013)... 21, 2013 Royal Philips Electronics (NYSE: PHG, ... first portable ultrasound with Philips, industry leading Live 3D ... CX50 xMATRIX with available Live 3D TEE and ICE ... at the EuroPCR, official meeting for the European Association ... Since its launch in 2012, Philips CX50 xMATRIX has ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2
... Rochelle, NY, March 4, 2009--The disposable bioprocessing market ... preparation toward a range of products for cell ... Genetic Engineering & Biotechnology News (GEN). Increasing ... completely disposable bioprocess stream is feasible and even ...
... that dramatically strengthens stem cells, ability to regenerate damaged ... diseases such as myopathy and muscular dystrophy, according to ... The world-first procedure has been successfully used to ... be applied to all tissue-based illnesses in humans such ...
... athletes suddenly collapse, it can be due to hereditary cardiac ... a genetic modification that leads to cardiac weakness in an ... a heart condition. Since the fish have a genetic makeup ... for humans as well. Cardiac insufficiency is ...
Cached Biology News:GEN reports biomanufacturers target a fully disposable process stream 2Stem cell breakthrough gives new hope to sufferers of muscle-wasting diseases 2Why 'lazy Susan' has a weak heart 2
...
... is obtained from non-demolished blood ... fasted donors. The donors are ... and are maintained on an ... Protein Concentration : 85 mg/ml ...
Hamster serum...
... Filter Plates are offered in several versions. ... depth filter plates are ideal to prepare ... is simple, versatile, and necessary to prevent ... 10 um glass fiber and 20 um ...
Biology Products: